AST/ALT Ratio Predicts Cirrhosis in Patients With Chronic Hepatitis C Virus Infection

Sheth, Sunil G.; Flamm, Steven L.; Gordon, Fredric D.; Chopra, Sanjiv

doi:10.1111/j.1572-0241.1998.044_c.x

Cited by 471 publications

(232 citation statements)

References 18 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…In the case of the GOT of the final consultation greater than 60 IU (OR 3.267, p = 0.002) it is in accordance with the study of Sheet et al, showing a GOT/GPT ratio greater than 1, where a histopathological worsening and clinical progression to cirrhosis occurs in patients with chronic C virus infection [28].…”

Section: Discussionsupporting

confidence: 78%

Variables Associated with Cirrhosis Diagnosis in Patients with Chronic Hepatitis C: A Case-Control Study

Sousa¹,

Costa²,

Souza³

et al. 2015

Health

View full text Add to dashboard Cite

The diagnosis of liver cirrhosis in patients with chronic hepatitis C has not always been easy, since the gold standard method is the liver biopsy, which is an invasive procedure with interobserver accuracy problems and there have been reports of complications including records of deaths due to hemoperitoneum. Cirrhosis changes the prognosis of the subject with hepatitis C and requires a different clinical management. This study aimed to identify clinical and laboratory variables associated with the diagnosis of cirrhosis in the ultrasonography of patients infected with hepatitis C. In a case-control study, we evaluated 70 cirrhotic patients with chronic hepatitis C compared to a control group of 70 non-cirrhotic people with positive HCV. The results showed, through logistic regression analysis, that the variables blood donor and professional athlete, adjusted for alcohol consumption, showed OR 0.24 and 0.18, with p values of 0.044 and 0.035, respectively. We conclude that the diagnosis of cirrhosis in patients with chronic hepatitis C remains challenging, but the patients with the condition of blood donor or professional athlete prove to be less likely to cirrhosis in ultrasonography in the initial consultation.

show abstract

Section: Discussionsupporting

confidence: 78%

Variables Associated with Cirrhosis Diagnosis in Patients with Chronic Hepatitis C: A Case-Control Study

Sousa¹,

Costa²,

Souza³

et al. 2015

Health

View full text Add to dashboard Cite

show abstract

“…The lower GPT in the TAI group may represent more progressive liver cirrhosis because the ratio of GOT/GPT in the TAI group [median: 1.27 (0.45–3.17)] was significantly higher compared with that in the TAE group [median: 1.03 (0.33–1.81); p < 0.01] [23, 24]. Therefore, the baseline characteristics of the patients in the TAI group appear to be slightly worse than those in the TAE group.…”

Section: Discussionmentioning

confidence: 99%

“…However, there were no significant differences in survival between TAE and TAI (data not shown). In general, TAE is selected for advanced HCC patients with adequate hepatic reserve and TAI is selected only for advanced HCC patients with poor hepatic reserve, because we believe that TAE is superior to TAI in its therapeutic effect as well as survival [22, 23, 24, 25]. In this study, however, TAE did not show a better improvement in the survival of patients with HCC compared with TAI, and, therefore, it is questionable whether TAE is really superior to TAI in survival.…”

Section: Discussionmentioning

confidence: 99%

Transcatheter Arterial Chemotherapy with and without Embolization in Patients with Hepatocellular Carcinoma

et al. 2004

View full text Add to dashboard Cite

Objective: This study compared the antitumor effect, adverse effects and survival between transcatheter arterial embolization (TAE) and transcatheter arterial infusion chemotherapy (TAI) in patients with hepatocellular carcinoma (HCC). Methods: The study population consisted of 168 consecutive patients with advanced HCC treated with transcatheter arterial treatments using cisplatin suspended in lipiodol. Among these, 74 patients were treated with TAE, and the remaining 94 patients were treated with TAI. Results: There were no significant differences in any baseline characteristics except hemoglobin, platelets, albumin, and glutamic pyruvic transaminase. Complete or partial tumor response was achieved in 54 patients (73%) in the TAE group and in 48 patients (51%) in the TAI group (p < 0.01). There were two treatment-related deaths caused by acute hepatic failure and acute renal failure in the TAE group. Nausea and deterioration of serum transaminase after TAE were significantly more severe than after TAI. Median survival time and survival rates at 5 years were 3.1 years and 25% in the TAE group, and 2.5 years and 18% in the TAI group (p = 0.37). Conclusion: TAE has a higher antitumor effect than TAI, but does not significantly improve the survival of patients with HCC.

show abstract

“…The strong influence of serum aminotransferase levels, HAI and fibrosis on SI in HCV-infected patients indicate that inflammatory activities and hepatic cell damage caused by HCV infection disturb glucose homeostasis in these patients. Serum aminotransferase levels are surrogate markers of liver cell integrity [23]and the AST/ALT ratio may predict cirrhosis in patients with HCV-induced liver disease [27]. Fibrosis correlates with the prognosis of developing cirrhosis during chronic HCV infection [28]and is closely related to necroinflammatory activities in HCV infection [29].…”

Section: Discussionmentioning

confidence: 99%

Severity of HCV-Induced Liver Damage Alters Glucose Homeostasis in Noncirrhotic Patients with Chronic HCV Infection

Konrad

Zeuzem²,

Toffolo

et al. 2000

Digestion

View full text Add to dashboard Cite

Background/Aims: To investigate the link between hepatitis C infection and glucose intolerance, we measured insulin sensitivity, glucose effectiveness and β-cell secretion in noncirrhotic HCV-infected patients with normal glucose tolerance according to WHO criteria as assessed by oral glucose tolerance tests. Methods: Glucose, insulin and C-peptide data from frequently sampled intravenous glucose tolerance tests were analyzed using the minimal modeling technique for glucose and C-peptide to determine insulin sensitivity, glucose effectiveness, first and second phase insulin secretion in noncirrhotic HCV-infected patients (n = 10) and in healthy control subjects (n = 10). Histological activity index (HAI) as well as the extent of fibrosis were evaluated by scoring liver biopsies. Results: Insulin sensitivity (2.72 ± 1.63 vs. 6.84 ± 1.20 10^–4 min^–1 per µU/ml, p < 0.01) and glucose effectiveness (2.29 ± 0.45 vs. 2.89 ± 0.39 10^–2 min^–1, p < 0.05) ere significantly lower in patients with HCV-induced liver disease. Insulin sensitivity was negatively related to serum alanine aminotransferase (r = –0.47, p < 0.05) and aspartate aminotransferase concentrations (r = –0.65, p < 0.05). Multiple linear regression analysis revealed a strong relation of insulin sensitivity with fibrosis score and HAI (r = –0.82, p < 0.02 for both). Second phase insulin secretion was significantly enhanced in HCV-infected patients (14.30 ± 2.04 vs. 8.29 ± 1.65 min^–1, p < 0.05). Conclusions: HCV-infected patients with normal glucose tolerance are insulin and glucose resistant. The impairment of glucose tolerance appears to be closely related with the severity of HCV-induced liver damage.

show abstract

AST/ALT Ratio Predicts Cirrhosis in Patients With Chronic Hepatitis C Virus Infection

Abstract: The AST/ALT ratio is a dependable marker of fibrosis stage and cirrhosis in patients with chronic HCV infection.

Cited by 471 publications

References 18 publications

Variables Associated with Cirrhosis Diagnosis in Patients with Chronic Hepatitis C: A Case-Control Study

Variables Associated with Cirrhosis Diagnosis in Patients with Chronic Hepatitis C: A Case-Control Study

Transcatheter Arterial Chemotherapy with and without Embolization in Patients with Hepatocellular Carcinoma

Severity of HCV-Induced Liver Damage Alters Glucose Homeostasis in Noncirrhotic Patients with Chronic HCV Infection

Contact Info

Product

Resources

About